Zongertinib could become a new tool in the treatment of HER-2 mutated lung cancer, specially for an specific group of patients
New oral drug shows high efficacy in HER2-mutated lung cancer Read More »
A type of autoantibodies is demonstrated to be an independent risk factor for the severity of COVID-19
New study on the causes of severe COVID-19 in vaccinated patients Read More »
Kleptomania is described for the first time not only as an impulsive disorder, but also as a compulsive disorder.
Kleptomania: Bellvitge leads a new approach in the study and treatment of the disease Read More »
The new tools are highly efficient, operate at colder temperatures, and appear to be more specific than the canonical system.
Dr. Roser Velasco, IDIBELL principal investigator at Neuro-Oncology group and neurologist at the Neuro-Oncology Unit of ICO Hospitalet and Bellvitge University Hospital, has co-directed the writing of an international guide of recommendations on the management of neurological complications associated with CAR-T cell therapy. Dr. Velasco has participated as an expert in neuro-oncology within the Committee
